Gall Bladder Status Among Children With Chronic Haemolytic Anemia (GBSACWCHA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03533322|
Recruitment Status : Unknown
Verified May 2018 by Shohnda Mohammed Nazeir, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : May 23, 2018
Last Update Posted : July 31, 2018
Gall bladder status among children with chronic haemolytic anemia attending to Assuit University Children Hospital.
Hemolysis is defined as the premature destruction of red blood cells (RBCs) (a shortened RBC life span). Anemia results when the rate of destruction exceeds the capacity of the marrow to produce RBCs. Normal RBC survival time is 110-120 days (half-life: 55-60 days), and thus, approximately 0.85% of the most senescent RBCs are removed and replaced each day.
Patients with chronic haemolytic anemia are subjected to many complications of chronic haemolytic anemia e.g anemic heart failure, complications of blood transfusion as hepatitis and AIDS, hypersplenism, haemosiderosis ,among them there is incidence of gallbladder stone formation.
This work aims to a) to determine the prevalence of gall bladder diseases among patient with chronic haemolytic anemia.
b) to determine the risk factors of gall bladder diseases among patients with chronic haemolytic anemia.
|Condition or disease|
|Gall Bladder Disease|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Gall Bladder Status Among Children With Chronic Haemolytic Anemia Attending to Assuit University Children Hospital|
|Estimated Study Start Date :||October 1, 2018|
|Estimated Primary Completion Date :||October 1, 2019|
|Estimated Study Completion Date :||October 1, 2019|
- prevelance of gall bladder diseases in children with chronic hemolytic syndrome [ Time Frame: one year ]gall bladder diseases
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03533322
|Contact: shohnda nazeir, firstname.lastname@example.org|
|Principal Investigator:||abelatif abdelmoez, professor||assiut universitypediatric hospital|
|Principal Investigator:||shereen galal, assistprof||assiut universitypediatric hospital|